Literature DB >> 1917622

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

C A Lawton1, M Won, M V Pilepich, S O Asbell, W U Shipley, G E Hanks, J D Cox, C A Perez, W T Sause, S R Doggett.   

Abstract

Significant late intestinal and urinary morbidity from external beam irradiation for adenocarcinoma of the prostate has been a constant concern of both the urologist and the radiation oncologist. We analyzed two large Radiation Therapy Oncology Group trials (7506 and 7706) using primary irradiation in the treatment of local or locoregional adenocarcinoma of the prostate to assess morbidity via the Radiation Therapy Oncology Group scoring scheme (grade 1-5). One thousand twenty patients were treated in total with a minimum follow-up of 7 years in the surviving patients. There was a 3.3% incidence of intestinal complications defined as grade 3 toxicity or more with .6% of patients experiencing bowel obstruction or perforation. Urinary complications defined as grade 3 toxicity or more were found in 7.7% of patients with only 0.5% experiencing morbidity that would require a major surgical intervention such as laparotomy, cystectomy, or prolonged hospitalization. Intestinal and urinary complications were evaluated in reference to several parameters that might have an impact on their incidence (i.e., previous laparotomy, stage of disease, hypertension, positive lymph nodes, previous transurethral resection, total dose, and energy of accelerator used). Only total dose (greater than 70 Gray) was found to have a significant impact on the incidence of the urinary complications. None of these factors had a significant impact on the incidence of intestinal complications. These data from two large multi-institutional trials represent a fair estimate of the actual incidence of major intestinal and urinary complications from external beam irradiation in the management of local and locoregional adenocarcinoma of the prostate. Since the incidence of these major complications remains very low, we believe that external beam irradiation remains an excellent alternative to radical prostatectomy in the management of these patients.

Entities:  

Mesh:

Year:  1991        PMID: 1917622     DOI: 10.1016/0360-3016(91)90732-j

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  42 in total

1.  Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser.

Authors:  Dharam Kaushik; Benjamin A Teply; George P Hemstreet
Journal:  Lasers Med Sci       Date:  2012-02-28       Impact factor: 3.161

2.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

3.  [Probability of seminal vesicle involvement in localized prostatic carcinoma. Significance in conformal radiotherapy].

Authors:  H J Feldmann; J Breul; F Zimmermann; S Wachter; T Wiegel
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

Review 4.  Management of Lower Urinary Tract Symptoms after Prostate Radiation.

Authors:  Pansy Uberoi; Charlton A Smith; Alvaro Lucioni
Journal:  Curr Urol Rep       Date:  2021-05-27       Impact factor: 3.092

5.  Treatment- and disease-related complications of prostate cancer.

Authors:  Anne R Simoneau
Journal:  Rev Urol       Date:  2006

Review 6.  The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

Authors:  Tony Y Eng; Join Y Luh; Charles R Thomas
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 3.092

7.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

8.  Radiation colitis and proctitis.

Authors:  Gregory D Kennedy; Charles P Heise
Journal:  Clin Colon Rectal Surg       Date:  2007-02

9.  Aplastic anemia associated with severe hemorrhagic cystitis following radiotherapy for prostate cancer.

Authors:  Taito Nakano; Kouji Izumi; Aerken Maolake; Ariunbold Natsagdorji; Hiroaki Iwamoto; Yasuhide Kitagawa; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  Mol Clin Oncol       Date:  2016-02-25

10.  Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis.

Authors:  Cem Onal; Erkan Topkan; Esma Efe; Melek Yavuz; Serhat Sonmez; Aydin Yavuz
Journal:  Radiat Oncol       Date:  2009-05-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.